40
Participants
Start Date
January 31, 1999
Primary Completion Date
September 30, 2003
Study Completion Date
May 31, 2005
recombinant human growth hormone
The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital, Gothenburg
Collaborators (1)
Pfizer
INDUSTRY
Göteborg University
OTHER